Last Monday was R&D day for Amgen and that should have provided the company an opportunity to show case itself as a company with attractive long-term growth prospects. Unfortunately, the reception fell flat. Amgen’s shares gave up all of their gains for the past year, and traditional fundamental analysis doesn’t explain why. The company is the world’s largest biotech company, the company holds three blockbuster drugs of revenues greater than a billion, has been profitable since 1991, and boasts a cash balance of over $5 billion. Yet, the stock has performed worse than some unprofitable biotech companies that don’t have a single product on the market.
Apparently, Wall Street is worried about Medicare reimbursement and has concerns that Amgen’s pipeline isn’t overflowing with products in late-stage development, causing investors to fret about Amgen’s future growth despite the fact that the company has said its 2005 earnings and revenue should be consistent with its annual growth projections through 2005. The company expects earnings of $2.71 per share to $2.85 per share next year on an adjusted basis, excluding items, and revenue of $11 billion to $11.5 billion.
More recently, Amgen said on March 29, it will acquire the roughly 80 percent of Tularik that the company does not already own for $1.3 billion in an all-stock deal. The acquisition gives Amgen access to technology designed to treat cancer and inflammatory diseases by regulating genes. The deal is expected to close by the second half of the year. With the Tularik’s acquisition, Amgen said it expects 2004 earnings of $2.30 per share to $2.40 per share and revenue of $9.7 billion to $10.4 billion. Wall Street liked the news and gave Amgen “thumbs up” on the acquisition as the company continues to find ways to fuel its pipeline.
Tularik’s gene-regulation technology focuses on selectively blocking the cascade of chemical reactions in the body that can cause diseases, including inflammation, which has been increasingly linked to major illnesses such as cancer, arthritis and heart disease. We believe the acquisition bodes well with Amgen. As we had said in our February 2004 report, if all goes well in Tularik’s pipeline, 2004 should prove to be an interesting and rewarding year for Tularik.
Amgen has several programs that, which target multi-million dollar indications and should attract investors’ attention. These include an antibody, AMG-162 that could enter Phase III trials later this year for osteoporosis, BVT 3498 in Phase II clinical trials targeting a novel pathway for diabetes, AMG-531 a platelet-stimulating drug in Phase II, and AMG-548, a novel antibody targeting inflammation in Phase II.
We believe that Amgen trades at a reasonable valuation and that clarity on Medicare reimbursement will create upside potential. Increase sales of Enbrel for psoriasis and Aranesp, will help the company meet its earnings guidance in the next 12 months. We continue to rate Amgen as a “buy” with a price target of $80. And for Tularik, given its current valuation, we rate it as a hold/sell.
DISCLAIMER
Information transmitted via BioSpace.com has been provided by publisher, Nadine Wong, of the “Biotech Sage Report” Investment Newsletter and all comments and opinions are solely those of Nadine Wong. Information provided is not guaranteed as to completeness or accuracy by Nadine Wong (the “Biotech Sage Report” publisher), BioSpace, Inc., or any person. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company. The security portfolio of the editor of this newsletter, our employees, principals or affiliated companies may, in some instances, include securities and/or options on securities mentioned in each issue. Additional information is available upon request. Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. The Information and views provided by the “Biotech Sage Report” Newsletter are prepared by Nadine Wong, and in no way reflect the views or efforts of BioSpace, Inc., any of BioSpace’s employees or officers. BioSpace, and BioSpace’s employees and officers, as well as (www.biotechnav.com) Wong & Wong, Inc, and Wong & Wong Inc.'s employees and officers, in no way accept responsibility for any of the Newsletter’s content.
While all reasonable care has been taken to ensure that the Information contained herein is presented in good faith, and is not untrue or misleading at the time of publication, BioSpace, Inc. and Nadine Wong make no representation as to its accuracy or completeness and it should not be relied upon as such. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. From time to time, BioSpace, Inc. and any officers or employees of BioSpace, Inc., as well as Nadine Wong and or (www.biotechnav.com) Wong & Wong, Inc., and any officers or employees of Wong & Wong, Inc., may, to the extent permitted by law, have a position or otherwise be interested in any transactions, in any investments (including derivatives) directly or indirectly in the subject of this report. Also BioSpace, Inc. and (www.biotechnav.com) Wong & Wong, Inc., may, from time to time solicit business from any company mentioned in this report. This report is provided solely for the information of viewers of BioSpace.com and/or viewers and subscribers of the Newsletters, who are expected to make their own investment decisions without reliance on this report. Neither BioSpace, Inc. nor any officer or employee of BioSpace, Inc., nor Nadine Wong or (www.biotechnav.com) Wong & Wong, Inc., or any officer or employee of Wong & Wong, Inc., accepts any liability whatsoever for any direct, indirect, special or consequential damages or loss arising from any use of this report or their contents. This report may not be reproduced, distributed or published by any recipient for any purpose without the prior express consent of the publishers. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, trademark or copyright of BioSpace.com, Nadine Wong or (www.biotechnav.com) Wong & Wong, Inc., or any third party.
The value of the investment(s) to which this report relates and their income yield(s) may go up or down. The investment(s) referred to in this report may not be suitable for private investors: if you are in any doubt you should seek advice from your investment advisor. Changes in rates of currency exchange may have an adverse effect on the value, price or income of investments. Statements as to past performance of any investment are not a guide to future performance. The levels and bases of taxation can change, and if you are in doubt you should seek independent professional advice. In some cases it may be difficult for you to sell or realize your investment or to obtain reliable information about its value or the extent of the risks to which you are exposed.
THIS INFORMATION IS PROVIDED “AS IS” AND NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED OF ACCURACY, MERCHANTIBILITY FITNESS FOR A PARTICULAR PURPOSE OR OF ANY OTHER NATURE ARE MADE WITH RESPECT TO THIS INFORMATION OR TO ANY EXPRESSED VIEWS PRESENTED IN THIS INFORMATION.
